RESEARCH ARTICLE |
|
Year : 2003 | Volume
: 20
| Issue : 1 | Page : 40-45 |
|
A randomized comparative study of tamsulosin vs placebo in the treatment of benign prostatic hyperplasia
NK Mohanty, RP Arora, Rajiba L Nayak, Vineet Malhotra
Department of Urology, V.M. Medical College and Safdarjang Hospital, New Delhi, India
Correspondence Address:
N K Mohanty C-II/124, Moti Bagh-1, New Delhi - 110 021 India
 Source of Support: None, Conflict of Interest: None  | Check |

|
|
Objective: The rationale of using α1, blockers in the management of benign prostatic hyperplasia (BPH) is based upon blocking the adrenergic receptors which regulate urinary outflow The prostate adenoma is predominantly stromal, having 40% of smooth muscle innervated by sympathetic adrenergic nerves stimulation of which accounts for 50% of outflow obstruction. Tamsulosin is an uroselective α1a/d blocker, controls both the lower urinary irritative and obstructive symptoms. The present study is a placebo controlled study evaluating the efficacy, safety and advantages of tamsulosin in the management of BPH.
Methods: A total number of 72 patients between 40-80 years of age were randomized to two groups. One group (38 patients) received tamsulosin (0.4 mg) daily and the other group (34 patients) received placebo for a period of two months with periodic follow up at 2nd , 4 th and 8 th week with IPSS (International Prostate Symptom Score) and uroflowmetry and ultrasonography at 8 th week.
Results: Our results show tamsulosin to be very effective in the management of BPH cases, not requiring surgery, with few side effects and good patient compliance. The improvement was seen both in IPSS (total, obstructive and irritative) and in urodynamic parameters. The differences were consistently superior with tamsulosin as compared to placebo in both the IPSS as well as uroflowmetry measurements.
Conclusion: Tamsulosin was found to be a very safe, well tolerated drug showing significant improvement in urinary outflow symptoms, reducing post void urine volume and decreasing IPSS with minimal tolerable adverse events. |
|
|
|
[FULL TEXT] [PDF Not available]* |
|
 |
|